← back to search

Xiaoyan Li

Shandong University · CN
Area of research
Oncology · Genetics
Research interest
Research focused on Breast cancer and KRAS, with related work in Metastasis, Cancer research, Lung cancer. Notable publications include 'circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer', 'Enhanced and Differential Capture of Circulating Tumor Cells from Lung Cancer Patients by Microfluidic Assays Using Aptamer Cocktail', and 'Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer'.
h-index
citations
542
works
7
NIH funding
primary concept
email

Recent publications

Developing a deep learning-based imaging diagnostic framework, PVDNet, for differentiating pulmonary artery sarcoma and pulmonary thromboembolism: a multi-center observational study
The Lancet Regional Health - Western Pacific 2025cited by 1position: middledoi
Cancer stem cells and their niche in cancer progression and therapy
Cancer Cell International 2023cited by 59position: lastdoi
Identification and validation of immunogenic cell death-related score in uveal melanoma to improve prediction of prognosis and response to immunotherapy
Aging 2023cited by 13position: firstdoi
A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Journal of Clinical Oncology 2022cited by 33position: middledoi
Disordered farnesoid <scp>X</scp> receptor signaling is associated with liver carcinogenesis in <scp><i>Abcb11</i></scp>‐deficient mice
The Journal of Pathology 2021cited by 26position: middledoi
Changes and sex- and age-related differences in the expression of drug metabolizing enzymes in a KRAS-mutant mouse model of lung cancer
PeerJ 2020cited by 6position: firstdoi
circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer
Oncogene 2019cited by 163position: middledoi
Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer
Molecular Therapy — Nucleic Acids 2019cited by 99position: middledoi
Enhanced and Differential Capture of Circulating Tumor Cells from Lung Cancer Patients by Microfluidic Assays Using Aptamer Cocktail
Small 2016cited by 131position: middledoi
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
BMC Cancer 2013cited by 84position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yaming Li · Shanghai Medical College of Fudan University2 papers (2019–2019)Xiaojin Song · University of Shanghai for Science and Technology2 papers (2019–2019)Guoyin Li · Zhengzhou University2 papers (2023–2023)Sijing Zeng · Guangzhou University of Chinese Medicine2 papers (2020–2021)Wenjing Zhao · Kunming University of Science and Technology2 papers (2019–2019)Lijuan Wang · Pingdingshan University2 papers (2019–2019)Yiran Liang · Fudan University2 papers (2019–2019)Tingting Ma · China Pharmaceutical University2 papers (2019–2019)Qifeng Yang · Qilu Hospital of Shandong University2 papers (2019–2019)Zhongqiu Liu · Guangzhou University of Chinese Medicine2 papers (2020–2021)Peng Su · North China University of Science and Technology2 papers (2019–2019)Renbo Guo · Shandong University2 papers (2019–2019)Yuting Sang · Shanghai Medical College of Fudan University2 papers (2019–2019)Hanwen Zhang · Shihezi University2 papers (2019–2019)Ning Zhang · Chinese University of Hong Kong2 papers (2019–2019)Ying Liu · Tangshan People's Hospital2 papers (2019–2019)Bing Chen · Guangzhou University of Chinese Medicine2 papers (2019–2019)Zhen Zhang · Southern Medical University1 papers (2016–2016)Jinping Wang · The First Affiliated Hospital, Sun Yat-sen University1 papers (2023–2023)Xiaomeng Liu · Qingdao University1 papers (2023–2023)